I would agree with you about at least one of the likely reasons being related to the hold. The SEC would likely be forced to wait on investigating any disclosure related to this as it probably involves business and trial related consequences. Neither NWBO or regulators would want undue pressure placed on them to unblind or give patients access to the treatment if efficacy or a high probabiluty of it in a significant group of patients has been determined. Waiting for trial results and or validation of newer processes would the prudent course of action. In the mean time this waiting gives cover for any additional discovery being worked on by various groups involved in the investigation. A search for moles within SEC or regulators might also be cause to keep everything quiet. As we now know from the sleuthing of sentiment_stocks and perhaps others, an undisclosed conflict of interest with someone on the DMB would be of interest to those doing any investigation. That person is no longer on that board and perhaps the SAB is acting more in line with that responsibility until right near the end of the trial because of this. Best wishes.
News 
Market Data 
Discover 
